1. Poland Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Mabion SA

Mabion SA

1.87
EUR
0.00
(0.00%)
-0.82EPS
28.38MMarket Cap
Nov 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.08
0.25
- -
- -
- -
- -
- -
3.66
10.15
9.38
4.27
0.97
1.09
Basic EPS, GAAP
-0.49
-0.44
-3.91
-4.84
-4.91
-5.26
-4.64
-4.06
0.12
1.43
2.55
-0.39
-3.87
-3.51
Free Cash Flow per Basic Share
-3.48
-2.42
-2.98
-1.32
-4.59
-2.97
-3.13
-2.81
-4.15
1.37
-2.5
1.7
-2.63
-2.14
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
54.79
5.14
4.07
0.32
-4.59
3.07
-1.57
-5.64
3.3
4.73
7.29
6.9
3.02
1.49
Tangible Book Value per Share
54.79
5.14
4.07
0.32
-4.59
3.02
-1.68
-5.71
3.25
4.69
7.26
6.88
3.01
1.49
Basic Weighted Avg Shares
8
10
11
12
12
13
14
14
16
16
16
16
16
16
Sales/Revenue/Turnover
- -
1
3
- -
- -
- -
- -
- -
57
164
152
69
16
18
Operating Margin (%)
100
100
-1,627.11
- -
- -
- -
- -
- -
-12.18
16.16
45.18
-1.64
-319.62
-237.05
Depreciation Expense
- -
- -
5
7
8
11
11
10
9
9
7
9
9
9
Net Income, GAAP
-4
-4
-43
-56
-58
-69
-64
-56
2
23
41
-6
-63
-57
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.29
- -
- -
- -
Profit Margin (%)
-67,089.66
-537.47
-1,556.57
- -
- -
- -
- -
- -
3.35
14.14
27.21
-9.18
-397.37
-321.43
Working Capital
-115
2
-12
-50
-110
6
-46
-93
-14
8
35
7
-31
-32
LT Debt
- -
- -
- -
- -
4
3
4
3
2
4
3
2
11
25
Total Equity
521
56
45
4
-54
42
-22
-77
53
77
118
111
49
24
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
38.37
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
35.49
- -
- -
- -
Return on Common Equity (%)
-1.11
-1.55
-84.24
-227.01
- -
- -
- -
- -
- -
35.73
42.48
-5.53
-78.14
-93.99

Capital Structure

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
7
7
LT Borrowings
10
17
24
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
112
144
122

Working Capital

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
13
14
15
Cash, Cash Equivalents & STI
6
7
6
Accounts Receivable, Net
2
4
1
Inventories
1
1
6
Total Current Liabilities
44
46
47
Payables & Accruals
- -
- -
- -
ST Debt
1
7
7
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-184.76%
-26.6%
-56.19%
Free Cash Flow
-59.74%
-154.42%
-254.3%
Net Income, GAAP
190.04%
373.29%
888.54%
Sales/Revenue/Turnover
- -
- -
-77.17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34
30
1
5
69
2025
3
- -
4
6
16
2026
5
3
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.09
0.64
-1.01
-1.11
-0.39
2025
-0.94
- -
-0.67
-1.31
-3.87
2026
-0.6
-0.92
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gregor Kawaletz
Full Time Employees
205
Sector
Health technology
Industry
Biotechnology
Address
Medical Biotechnology Scientific and Industrial Complex Konstantynów Lódzki LDZ Poland 95-050
IPO Date
Aug 10, 2010
Website
mabion.eu
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Mabion S.A. operates as a specialized biotechnology firm, having evolved into a comprehensive Contract Development and Manufacturing Organization (CDMO) for advanced biologics. The company delivers end-to-end GMP development and manufacturing services, concentrating on intricate biotherapeutics including monoclonal antibodies, bispecifics, Antibody-Drug Conjugates (ADCs), recombinant proteins, and vaccine antigens. From its facilities in Konstantynów Łódzki, Poland, established in 2007, Mabion supports global pharmaceutical partners across all stages, from initial cell line development and process optimization to drug substance production and sterile fill & finish. While maintaining its foundational work on proprietary therapeutic candidates like MabionCD20 and MabionHER2, the company's strategic focus is expanding its CDMO capabilities, particularly in Drug Substance manufacturing and engaging in co-development ventures. Recent alliances, such as a collaboration with NovalGen on a pioneering T-cell engager entering clinical trials for cancer immunotherapy, underscore its dedication to bringing cutting-edge treatments to market.